Gene: SORCS2

57537
-
sortilin related VPS10 domain containing receptor 2
protein-coding
4p16.1
Ensembl:ENSG00000184985 MIM:606284 Vega:OTTHUMG00000159981 UniprotKB:Q96PQ0
NC_000004.12
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.369e-1 (AD)  5.518e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg17394237chr4:7196466SORCS2Gene body1.901e-4Alcohol use disorders26763658
cg12958891chr4:7706547SORCS2Gene body1.981e-4Alcohol use disorders26763658
cg06283478chr4:7649606SORCS25.800e-10Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TPCN10.867
TMEM1040.861
DAG10.838
TTYH10.835
LRRC8A0.832
FGFR30.813
SLC27A10.809
WFS10.79
CDH200.789
CADM10.785

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GADL1-0.503
FER1L6-0.466
GSDMA-0.463
WDR72-0.455
BMP5-0.449
OR4F5-0.445
C2orf83-0.429
FMO1-0.426
SPRR4-0.426
C17orf112-0.424

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of SORCS2 mRNA19933214
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
D020106AcrylamideAcrylamide results in decreased expression of SORCS2 mRNA28959563
D020106AcrylamideAcrylamide results in increased expression of SORCS2 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of SORCS2 mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of SORCS2 mRNA23630614
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of SORCS2 mRNA28522335
D001151ArsenicArsenic affects the methylation of SORCS2 gene25304211
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in increased expression of SORCS2 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SORCS2 mRNA21871943
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SORCS2 mRNA20713471|2222880
C006780bisphenol Abisphenol A results in increased expression of SORCS2 mRNA25594700
C006780bisphenol Abisphenol A affects the expression of SORCS2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of SORCS2 gene28505145
C013418bromfenacoumbromfenacoum results in increased expression of SORCS2 protein28903499
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of SORCS2 gene20938992
D016572CyclosporineCyclosporine results in decreased methylation of SORCS2 promoter27989131
D004041Dietary FatsDietary Fats results in increased expression of SORCS2 mRNA18042831|2501614
D004041Dietary FatsDietary Fats results in increased expression of SORCS2 mRNA21852083
C024629dimethyl phthalatedimethyl phthalate affects the expression of SORCS2 mRNA26924002
D004317DoxorubicinDoxorubicin affects the methylation of SORCS2 gene28962528
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of SORCS2 mRNA23649840
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of SORCS2 gene20938992
D005557FormaldehydeFormaldehyde results in increased expression of SORCS2 mRNA23649840
C039281furanfuran results in increased expression of SORCS2 mRNA27387713
D017313FenretinideFenretinide results in increased expression of SORCS2 mRNA28973697
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of SORCS2 mRNA20044591
D007545IsoproterenolIsoproterenol results in decreased expression of SORCS2 mRNA20003209
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of SORCS2 mRNA24796395
D007854LeadLead affects the expression of SORCS2 mRNA28903495
D015122MercaptopurineMercaptopurine results in increased expression of SORCS2 mRNA23358152
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of SORCS2 gene20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of SORCS2 mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of SORCS2 mRNA23649840
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of SORCS2 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of SORCS2 mRNA"25554681
D000073878Palm OilPalm Oil results in increased expression of SORCS2 mRNA18042831
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of SORCS2 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of SORCS2 mRNA26272509
C020806tetrabromobisphenol Atetrabromobisphenol A results in increased expression of SORCS2 mRNA25172293
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SORCS2 mRNA26377647
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of SORCS2 mRNA19933214
C009495titanium dioxidetitanium dioxide results in increased expression of SORCS2 mRNA23557971|2776080
D014028Tobacco Smoke PollutionTobacco Smoke Pollution affects the expression of SORCS2 mRNA20133372
D014212TretinoinTretinoin results in increased expression of SORCS2 mRNA23724009
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of SORCS2 mRNA24935251|2627250
D014520UrethaneUrethane results in decreased expression of SORCS2 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SORCS2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of SORCS2 mRNA23179753|2438349
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS2 mRNA"27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0008188neuropeptide receptor activity-NAS11499680  
GO ID GO Term Qualifier Evidence PubMed
GO:0007218neuropeptide signaling pathway-NAS11499680  
GO ID GO Term Qualifier Evidence PubMed
GO:0016020membrane-NAS11499680  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26174813New suggestive genetic loci and biological pathways for attention function in adult attention-deficit/hyperactivity disorder. (2015 Sep)Alemany SAm J Med Genet B Neuropsychiatr Genet